Premium
Imaging agents for myeloperoxidase
Author(s) -
Malmquist Jonas,
Bernlind Alexandra,
Johansson Maria,
Juréus Anders,
Nilsson Maria
Publication year - 2012
Publication title -
journal of labelled compounds and radiopharmaceuticals
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.432
H-Index - 47
eISSN - 1099-1344
pISSN - 0362-4803
DOI - 10.1002/jlcr.2961
Subject(s) - chemistry , myeloperoxidase , isotopologue , formate , potassium cyanide , in vivo , in vitro , cyanide , potassium , radiochemistry , catalysis , biochemistry , organic chemistry , molecule , medicine , microbiology and biotechnology , inflammation , biology
The myeloperoxidase (MPO) inhibitors 1 and 2 were prepared as their isotopologues with carbon‐14, carbon‐13, and nitrogen‐15 or tritium with high specific activity and purity. Starting from potassium [ 14 C]cyanide or [ 14 C]formate provided metabolically stable 14 C‐labels on [ 14 C]‐1 and [ 14 C]‐2. Catalytic hydrogenation was used for the preparation of [ 3 H]‐2, giving multiple enriched positions as shown by 3 H NMR. 1 and 2 are promising in vitro and in vivo imaging radioligands and have the potential to provide key information with regard to MPO expression, function, stoichiometry, and pharmacology.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom